secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001213900-24-044747
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax prices $2.25M public offering of common stock and warrants
-----------------------------------------------------------------

- Gross proceeds of ~$2.25M from offering of 1,666,667 shares/equivalents plus Series A-1 and A-2 warrants.
- Series A-1 warrants exercisable at $1.35/share, expire in 5 years; Series A-2 at $1.35/share, expire in 18 months.
- Proceeds to be used for working capital, general corporate purposes, and possibly settling a portion of an obligation.
- After closing, 2,741,600 shares of common stock outstanding.
- A.G.P./Alliance Global Partners acted as sole placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/0001213900-24-044747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024044747/ea0206438-8k_virpax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-044747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer